CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Pomalidomide

泊马度胺 杂质对照品Pomalidomide Impurities

49 个杂质条目49 impurity entries

本页汇总 泊马度胺 的 49 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 49 impurity reference standards of Pomalidomide. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 泊马度胺(Pomalidomide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsIdentification and characterization of related substances in pomalidomide by hyphenated LC-MS techniques
    Journal of pharmaceutical and biomedical analysis · 2015 · Lu P et al.  ·  PMID 26048668  ·  DOI
  2. 分析方法Analytical MethodsIdentification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
    Beilstein journal of organic chemistry · 2025 · Wang B et al.  ·  PMID 39996168  ·  DOI
  3. 分析方法Analytical MethodsA validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2015 · Iqbal M et al.  ·  PMID 25621435  ·  DOI
  4. 分析方法Analytical MethodsQuantification of Pomalidomide Using Conventional and Eco-Friendly Stability-Indicating HPTLC Assays: A Contrast of Validation Parameters
    ACS omega · 2023 · Alam P et al.  ·  PMID 37636909  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisMicrowave-assisted synthesis of pomalidomide building blocks for rapid PROTAC and molecular glue development
    Chemical communications (Cambridge, England) · 2025 · Abdallah DI et al.  ·  PMID 40063364  ·  DOI

泊马度胺 —— 原料药与杂质对照品Pomalidomide — drug substance & impurities

共 50 个条目(含原料药本体)50 items incl. the drug substance
Pomalidomide structure
原料药 APIAPI
泊马度胺Pomalidomide
Pomalidomide
CAS No.19171-19-8
Chemical FormulaC13H11N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 1 structure
1
泊马度胺杂质1Pomalidomide Impurity 1
Pomalidomide Impurity 1
CAS No.5054-59-1
Chemical FormulaC13H10N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 2 structure
2
泊马度胺杂质2Pomalidomide Impurity 2
Pomalidomide Impurity 2
CAS No.497147-11-2
Chemical FormulaC13H11N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 4 structure
4
泊马度胺杂质4Pomalidomide Impurity 4
Pomalidomide Impurity 4
CAS No.2635-64-5
Chemical FormulaC13H13N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 5 structure
5
泊马度胺杂质5Pomalidomide Impurity 5
Pomalidomide Impurity 5
CAS No.918314-45-1
Chemical FormulaC13H13N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 6 structure
6
泊马度胺杂质6Pomalidomide Impurity 6
Pomalidomide Impurity 6
CAS No.19171-18-7
Chemical FormulaC13H9N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 7 Dihydrate structure
7
泊马度胺杂质7 二水合物Pomalidomide Impurity 7 Dihydrate
Pomalidomide Impurity 7 Dihydrate
CAS No.1852533-96-0
Chemical FormulaC8H7NO4·HCl·2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 8 structure
8
泊马度胺杂质8Pomalidomide Impurity 8
Pomalidomide Impurity 8
CAS No.191732-76-0
Chemical FormulaC13H11N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 9 structure
9
泊马度胺杂质9Pomalidomide Impurity 9
Pomalidomide Impurity 9
CAS No.50-35-1
Chemical FormulaC13H10N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 10 structure
10
泊马度胺杂质10Pomalidomide Impurity 10
Pomalidomide Impurity 10
CAS No.1547162-41-3
Chemical FormulaC13H11N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 13 structure
13
泊马度胺杂质13Pomalidomide Impurity 13
Pomalidomide Impurity 13
CAS No.444289-17-2
Chemical FormulaC15H13N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 14 structure
14
泊马度胺杂质14Pomalidomide Impurity 14
Pomalidomide Impurity 14
CAS No.1001852-15-8
Chemical FormulaC13H13N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 16 structure
16
泊马度胺杂质16Pomalidomide Impurity 16
Pomalidomide Impurity 16
CAS No.156113-87-0
Chemical FormulaC11H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 20 structure
20
泊马度胺杂质20Pomalidomide Impurity 20
Pomalidomide Impurity 20
CAS No.202271-90-7
Chemical FormulaC13H11N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 21 structure
21
泊马度胺杂质21Pomalidomide Impurity 21
Pomalidomide Impurity 21
CAS No.202271-89-4
Chemical FormulaC13H11N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 22 structure
22
泊马度胺杂质22Pomalidomide Impurity 22
Pomalidomide Impurity 22
CAS No.1799711-24-2
Chemical FormulaC19H22N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 23 structure
23
泊马度胺杂质23Pomalidomide Impurity 23
Pomalidomide Impurity 23
CAS No.2022182-57-4
Chemical FormulaC18H20N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 24 structure
24
泊马度胺杂质24Pomalidomide Impurity 24
Pomalidomide Impurity 24
CAS No.2022182-59-6
Chemical FormulaC19H22N4O7
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 25 structure
25
泊马度胺杂质25Pomalidomide Impurity 25
Pomalidomide Impurity 25
CAS No.1950635-34-3
Chemical FormulaC28H38N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 26 structure
26
泊马度胺杂质26Pomalidomide Impurity 26
Pomalidomide Impurity 26
CAS No.2245697-88-3
Chemical FormulaC19H23N3O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 27 structure
27
泊马度胺杂质27Pomalidomide Impurity 27
Pomalidomide Impurity 27
CAS No.2093386-39-9
Chemical FormulaC18H22N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 28 structure
28
泊马度胺杂质28Pomalidomide Impurity 28
Pomalidomide Impurity 28
CAS No.2138439-12-8
Chemical FormulaC17H20N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 29 structure
29
泊马度胺杂质29Pomalidomide Impurity 29
Pomalidomide Impurity 29
CAS No.2093388-67-9
Chemical FormulaC19H23N5O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 30 structure
30
泊马度胺杂质30Pomalidomide Impurity 30
Pomalidomide Impurity 30
CAS No.2093416-31-8
Chemical FormulaC21H28N4O7
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 31 structure
31
泊马度胺杂质31Pomalidomide Impurity 31
Pomalidomide Impurity 31
CAS No.1818885-63-0
Chemical FormulaC27H32N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 32 structure
32
泊马度胺杂质32Pomalidomide Impurity 32
Pomalidomide Impurity 32
CAS No.2222114-22-7
Chemical FormulaC17H17FN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 33 structure
33
泊马度胺杂质33Pomalidomide Impurity 33
Pomalidomide Impurity 33
CAS No.2222114-64-7
Chemical FormulaC22H26N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 34 structure
34
泊马度胺杂质34Pomalidomide Impurity 34
Pomalidomide Impurity 34
CAS No.1001852-14-7
Chemical FormulaC13H13N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 38 structure
38
泊马度胺杂质38Pomalidomide Impurity 38
Pomalidomide Impurity 38
CAS No.103259-06-9
Chemical FormulaC9H9NO4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 39 structure
39
泊马度胺杂质39Pomalidomide Impurity 39
Pomalidomide Impurity 39
CAS No.144841-10-1
Chemical FormulaC11H11NO5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 41 structure
41
泊马度胺杂质41Pomalidomide Impurity 41
Pomalidomide Impurity 41
CAS No.200709-36-0
Chemical FormulaC11H11NO5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 42 structure
42
泊马度胺杂质42Pomalidomide Impurity 42
Pomalidomide Impurity 42
CAS No.34529-06-1
Chemical FormulaC10H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 43 structure
43
泊马度胺杂质43Pomalidomide Impurity 43
Pomalidomide Impurity 43
CAS No.21606-04-2
Chemical FormulaC9H7NO6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 44 structure
44
泊马度胺杂质44Pomalidomide Impurity 44
Pomalidomide Impurity 44
CAS No.6744-85-0
Chemical FormulaC9H7NO6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 45 structure
45
泊马度胺杂质45Pomalidomide Impurity 45
Pomalidomide Impurity 45
CAS No.13365-26-9
Chemical FormulaC10H9NO6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 46 structure
46
泊马度胺杂质46Pomalidomide Impurity 46
Pomalidomide Impurity 46
CAS No.22235-04-7
Chemical FormulaC10H7NO4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 51 structure
51
泊马度胺杂质51Pomalidomide Impurity 51
Pomalidomide Impurity 51
CAS No.1001852-10-3
Chemical FormulaC13H11N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 52 structure
52
泊马度胺杂质52Pomalidomide Impurity 52
Pomalidomide Impurity 52
CAS No.1547162-46-8
Chemical FormulaC13H11N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 53 structure
53
泊马度胺杂质53Pomalidomide Impurity 53
Pomalidomide Impurity 53
CAS No.1795373-54-4
Chemical FormulaC21H14N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 54 structure
54
泊马度胺杂质54Pomalidomide Impurity 54
Pomalidomide Impurity 54
CAS No.1795373-50-0
Chemical FormulaC16H8N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 55 structure
55
泊马度胺杂质55Pomalidomide Impurity 55
Pomalidomide Impurity 55
CAS No.2093388-21-5
Chemical FormulaC16H18N4O4·C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 56 structure
56
泊马度胺杂质56Pomalidomide Impurity 56
Pomalidomide Impurity 56
CAS No.1957235-67-4
Chemical FormulaC15H16N4O4·C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 57 structure
57
泊马度胺杂质57Pomalidomide Impurity 57
Pomalidomide Impurity 57
CAS No.18658-36-1
Chemical FormulaC13H12N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 58 structure
58
泊马度胺杂质58Pomalidomide Impurity 58
Pomalidomide Impurity 58
CAS No.92971-15-8
Chemical FormulaC8H4N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 59 structure
59
泊马度胺杂质59Pomalidomide Impurity 59
Pomalidomide Impurity 59
CAS No.4277-02-5
Chemical FormulaC8H4N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 60 structure
60
泊马度胺杂质60Pomalidomide Impurity 60
Pomalidomide Impurity 60
CAS No.2300-16-5
Chemical FormulaC8H4N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 61 structure
61
泊马度胺杂质61Pomalidomide Impurity 61
Pomalidomide Impurity 61
CAS No.90348-28-0
Chemical FormulaC8H4N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 62 structure
62
泊马度胺杂质62Pomalidomide Impurity 62
Pomalidomide Impurity 62
CAS No.24184-33-6
Chemical FormulaC10H16N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 63 structure
63
泊马度胺杂质63Pomalidomide Impurity 63
Pomalidomide Impurity 63
CAS No.39133-20-5
Chemical FormulaC12H11N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Pomalidomide Impurity 64 structure
64
泊马度胺杂质64Pomalidomide Impurity 64
Pomalidomide Impurity 64
CAS No.460741-57-5
Chemical FormulaC13H11N3O5
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

泊马度胺 —— 研究文献与合成路线Pomalidomide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 泊马度胺 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Pomalidomide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8
    Sun Z, Deng B, Yang Z, et al. · European journal of medicinal chemistry · 2022 · 被引 33cited 33
  2. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
    Li L, Wu Y, Yang Z, et al. · Bioorganic chemistry · 2021 · 被引 34cited 34
  3. Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries
    Brownsey DK, Rowley BC, Gorobets E, et al. · Chemical science · 2021 · 被引 40cited 40
  4. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
    Zhang F, Wu Z, Chen P, et al. · Bioorganic & medicinal chemistry · 2020 · 被引 35cited 35
  5. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation
    Chen H, Chen F, Pei S, et al. · Bioorganic chemistry · 2019 · 被引 34cited 34
  6. A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation
    Li L, Li Y, Ma X, et al. · Bioorganic chemistry · 2025 · 被引 5cited 5

合成路线文献Synthetic-route papers

  1. Microwave-assisted synthesis of pomalidomide building blocks for rapid PROTAC and molecular glue development
    Abdallah DI, Israelian J, Hasan LS, et al. · Chemical communications (Cambridge, England) · 2025
  2. Rapid synthesis of pomalidomide-conjugates in minutes <i>via</i> temperature elevation and delayed feeding
    Jiang Y, Zhao H, Chen L, et al. · Chemical communications (Cambridge, England) · 2025
  3. Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties
    Guo Y, Wang X, Wang Z, et al. · Pharmaceuticals (Basel, Switzerland) · 2022

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

泊马度胺 杂质谱研究要点Pomalidomide — impurity profiling notes

下面这些是拿到 泊马度胺 的 50 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 50 impurity entries for Pomalidomide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances